$LIMN

$2.90 -$0.02 (0.86%) Close

$LIMN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 1.3M shares outstanding

Who owns LIMN?

By type of holder

Institutions 70.6% Insiders 0.0% Everyone else 29.4%

Concentration Top 10 holders own 2014.1%

Chris Kim 717.8% · Valetudo Therapeutics LLC 717.8%

Institutional ownership

70.6%

-29.4 pts vs last qtr

Institutional holders

-1 vs last qtr

Net shares bought

−529.5K

by institutions in Q2 2026

New / sold out

4 / 5

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

XTX Topco Ltd NEW +221.8K
Goldman Sachs Group Inc NEW +40.2K

Biggest sellers in Q2 2026

Citadel Advisors LLC −621.4K
Jane Street Group, LLC SOLD OUT −71.3K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Liminatus Pharma Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+35.7%

+35.73% a year

Each share's claim on the business

−26.3%

shrank without buying or selling a share

Diluted shares, split-adjusted

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years27% Under 1 year73%

Quarterly turnover

39.2%

of institutional shares changed hands

Top 10 managers, median time held

1 year

Super Investors

Investment managers reporting LIMN on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
CA Citadel Advisors LLC	56.1K	4.19%	−621.4K (−91.7%)	Q4 '25	0.0%
Shares held by quarter Peak holding677.5K (Q1'26) Change over 8 quarters+56.1K Share of the company4.190% Citadel Advisors LLC's full portfolio →
CC Cygnus Capital Advisors, LLC	329.3K	24.58%	−20.7K (−5.9%)	Q1 '26	0.0%
Shares held by quarter Peak holding350.0K (Q1'26) Change over 8 quarters+329.3K Share of the company24.580% Cygnus Capital Advisors, LLC's full portfolio →

Citadel Advisors LLC

56.1K

% of company

4.19%

Change vs last qtr

−621.4K (−91.7%)

Held since

Q4 '25

Cygnus Capital Advisors, LLC

329.3K

% of company

24.58%

Change vs last qtr

−20.7K (−5.9%)

Held since

Q1 '26

17 more super investors behind a free account

See every manager holding Liminatus Pharma Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting LIMN on Form N-PORT; together they hold 11.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FE Fidelity Extended Market Index Fund Fidelity Concord Street Trust	$12.7K	77.3K	5.77%	0.00%	May 31, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$5.57K	50.4K	3.76%	0.00%	June 30, 2026

Fidelity Extended Market Index Fund

Fidelity Concord Street Trust

Position value

$12.7K

% of company

5.77%

% of the fund

0.00%

As of

May 31, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$5.57K

% of company

3.76%

% of the fund

0.00%

As of

June 30, 2026

3 more funds behind a free account

See every fund holding Liminatus Pharma Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
CK Chris Kim 5%+ holder 13D · 14.3%	9.6M	717.76%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company717.760% Disclosed stake13D · 14.3% View the 13D/G filing →
VT Valetudo Therapeutics LLC 5%+ holder 13D · 14.3%	9.6M	717.76%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company717.760% Disclosed stake13D · 14.3% View the 13D/G filing →

Chris Kim

5%+ holder13D · 14.3%

9.6M

% of company

717.76%

Change vs last qtr

—

Held since

—

Valetudo Therapeutics LLC

5%+ holder13D · 14.3%

9.6M

% of company

717.76%

Change vs last qtr

—

Held since

—

1 more holders behind a free account

See every insider and 5%+ holder of Liminatus Pharma Inc.

Comments